Edgar Filing: FATE THERAPEUTICS INC - Form 4

FATE THERAPEUTICS INC Form 4 January 10, 2014					
FORM 4 UNITED STAT	ES SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION	OMB AF OMB Number:	PPROVAL 3235-0287	
Section 16. Form 4 or Form 5 obligations may continue. Filed pursuant Section 17(a) of t	OF CHANGES IN BENEFICIAL ON SECURITIES to Section 16(a) of the Securities Exchan he Public Utility Holding Company Act (h) of the Investment Company Act of 1	January 31 2005 Estimated average burden hours per response 0.5			
(Print or Type Responses)					
1. Name and Address of Reporting Person Weyer Christian	2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE] 5. Relation: Issuer		p of Reporting Person(s) to Theck all applicable)		
(Last) (First) (Middle) C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200	3. Date of Earliest Transaction (Month/Day/Year) 01/09/2014	X Director X Officer (give below)		Owner er (specify	
(Street) SAN DIEGO, CA 92121	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Derivative Securities A		, or Beneficial	ly Owned	
(Instr. 3) any	tion Date, if TransactionAcquired (A) or Code Disposed of (D) h/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A) or	SecuritiesFeBeneficially(IOwned(I	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line for each	Code V Amount (D) Price th class of securities beneficially owned directly of	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) o Disposed of (D (Instr. 3, 4, and 5))		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.62	01/09/2014		А	100,000	<u>(1)</u>	01/08/2024	Common Stock	100,000

Edgar Filing: FATE THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
Weyer Christian C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUI SAN DIEGO, CA 92121	TE 200	Х		See remarks		
Signatures						
/s/ Cindy R. Tahl, as Attorney-in-Fact	01/10/20	14				
**Signature of Reporting Person	Date					
Explanation of Responses:						

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on November 4, 2013 such that this option is fully exercisable on October 4, 2017.
- (2) Not applicable.

Remarks:

President and Chief Executive Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.